Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability
作者:Ian Sellitto、Bertrand Le Bourdonnec、Karin Worm、Allan Goodman、Markku A. Savolainen、Guo-Hua Chu、Christopher W. Ajello、Christopher T. Saeui、Lara K. Leister、Joel A. Cassel、Robert N. DeHaven、Christopher J. LaBuda、Michael Koblish、Patrick J. Little、Bernice L. Brogdon、Steven A. Smith、Roland E. Dolle
DOI:10.1016/j.bmcl.2009.10.062
日期:2010.1
A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability pro. le in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF<br/>[FR] INHIBITEURS D'ADAPTATEUR DE SUBSTRAT DE PRMT5 ET LEURS UTILISATIONS
申请人:BROAD INST INC
公开号:WO2022032144A1
公开(公告)日:2022-02-10
Provided herein are compounds that modulate PRTM5 activity. The compounds may inhibit the binding PRMT5 with a PRMT5 substrate adaptor. The compounds can modulate PRMT5 methyltransferase activity, modulate transcription of a gene regulated by PRMT5, modulate chromatin structure regulation, modulate cellular differentiation, and/or modulate mRNA splicing, e.g., by disrupting binding of PRMT5 with a PRMT5 substrate adaptor. Also provided are pharmaceutical compositions comprising the compounds, methods of modulating PRTM5 activity, and methods of treating disease (e.g., cancer) in a subject by administering a compound or composition described herein.